[HTML] sciencedirect.com

[HTML][HTML] Characteristics of real-world commercially insured patients with treatment-resistant depression initiated on esketamine nasal spray or conventional therapies …

S Karkare, M Zhdanava, D Pilon, AI Nash… - Clinical Therapeutics, 2022 - Elsevier
Purpose This study aimed to characterize patients with treatment-resistant depression (TRD)
initiating esketamine or conventional therapies. Methods Adults with major depressive …
被引用次数：9 相关文章

Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in …

S Karkare, M Zhdanava, D Pilon, AI Nash… - Clinical …, 2022 - europepmc.org
Purpose This study aimed to characterize patients with treatment-resistant depression (TRD)
initiating esketamine or conventional therapies. Methods Adults with major depressive …

Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in …

S Karkare, M Zhdanava, D Pilon… - Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose This study aimed to characterize patients with treatment-resistant depression (TRD)
initiating esketamine or conventional therapies. Methods Adults with major depressive …
[HTML] clinicaltherapeutics.com

[HTML][HTML] Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional …

S Karkare, M Zhdanava, D Pilon… - Clinical …, 2022 - clinicaltherapeutics.com
Purpose This study aimed to characterize patients with treatment-resistant depression (TRD)
initiating esketamine or conventional therapies. Methods Adults with major depressive …